FDA: 5 hospitals granted special permit to treat COVID-19 patients with ivermectin | Inquirer News

FDA: 5 hospitals granted special permit to treat COVID-19 patients with ivermectin

/ 11:34 AM April 27, 2021

FDA: 3rd hospital secures compassionate special permit to use Ivermectin vs COVID-19


MANILA, Philippines — Five hospitals in the country have so far been granted compassionate special permits (CSP) to use human-grade ivermectin to treat COVID-19 patients, the Food and Drug Administration (FDA) said Tuesday.

FDA Director-General Eric Domingo confirmed in a text message to INQUIRER.net that the number of hospitals given CSP for ivermectin has increased to five.


Only three hospitals had a CSP to use the drug for COVID-19 patients on April 22.


In an interview on ABS-CBN News Channel, Domingo also disclosed that a company has expressed willingness to file for a certificate product registration (CPR) of imported ivermectin before the FDA.

He said representatives of the company, which he did not identify, have met with drug regulators in the country last week.

Prior to this development, local firm Lloyd Laboratories Inc. applied for a CPR of ivermectin for human use before the FDA.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, Eric Domingo, Ivermectin

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.